**Table D-75. Evidence table for studies addressing management of PPH (Oleen 1990)**

| **Study**  **Description** | **Intervention** | **Inclusion/Exclusion**  **Criteria & Population** | **Outcomes** |
| --- | --- | --- | --- |
| Author:  Oleen et al.,  199076  Country:US  Enrollment period:  Jan 1986 to March 1987  Birth setting:  Hospitals  Facility characteristics:  Multisite- 12 sites  Funding:  Upjohn Company  Design:  Case series | **Intervention:**  Carboprost tromethamine sterile solution (125 or 250 ug) intramuscular, intramyometrial, intravenous, intrauterine, or intracervical  **Groups:**  **G1:** intervention  N at enrollment:  **G1:** 237 (blood loss could not be estimated for 10 cases)  **G1a:** 215 success  **G1b:** 12 failure  Duration of treatment: NR  Timing of treatment: NR  Order of treatment: NR  Length of follow-up: NR | **Operational definition of PPH:** NR  **Definition of success of treatment**: Control of hemorrhage  **Method of blood loss measurement:** NR  **Severity:** NR  Inclusion criteria:   * Receipt of carboprost tromethamine at a study hospital * Data accessible in medical record   Exclusion criteria:   * See inclusion   **Maternal age, yrs, mean ± SD:**  **G1:** 25.3 ± 5.7  **Parity, n:**  Primiparous  **G1:** 108  Multiparous  **G1:** 113  Non-viable offspring  **G1:** 15  **Weeks gestation:** NR  **Single pregnancy:** NR  **Multiple pregnancy:** NR  **Race/ethnicity:** NR  **BMI:** NR  **Baseline hemoglobin:** NR  **SES:** NR  **Mode of birth, n:**  Cesarean  **G1:** 72 (30.4)  **Risk factors, n (%):**  Labor induction/augmentation  **G1:** 92 (38.8)  Fibroids  Preeclampsia (magnesium treated)  **G1:** 43 (18.1)  **Primary etiology of PPH, n (%):**  Chorioamnionitis  **G1:** 3 (1.3)  Retained products of conception  **G1:** 27 (11.4)  Lacerations  **G1:** 35 (14.8)  Peripheral coagulopathy  **G1:** 4 (1.7) | **Cessation of hemorrhage, immediate, n (%):**  **G1:** 208/237 (87.8)  **Cessation of hemorrhage, with further oxytocins:**  **G1:** 17/237  **Therapy failed:**  **G1:** 12/237 (5.1)  **Blood loss, ml mean (range):**  **G1:** 970 ± 955 (100-9500)  **G1a:** 900 ± 748 (100-9500)  **G1b:** 2229 ± 2454 (500-9500)  **Transfusion:**  RBC, n (%)  **G1:** 64 (27)  FFP, cryoprecipitate, or albumen, n (%)  **G1:** 9 (4)  **ICU admission:** NR  **Anemia:** NR  **Length of stay:** NR  **Mortality:** NR  **Uterine preservation:**  Hysterectomy  **G1:** 7  **Future fertility:** NR  **Breastfeeding:** NR  **Psychological impact:** NR  **Confounders:** NR  **Effect modifiers:** NR  **Harms pre-specified:** No  **Harms, n (%):** Diarrhea  **G1:** 27 (11.4)  Elevated blood pressure  **G1:** 16 (6.8)  Vomiting  **G1:** 16 (6.8)  Elevated temperature  **G1:** 5 (2.1)  Flushing  **G1:** 4 (1.7)  Tachycardia  **G1:** 4 (1.7) |